News | January 10, 2007

Atherosclerosis Drug Trial Approved

Jan 11, 2007 — FDA approval last week of Anthera’s Investigational New Drug (IND) application for its lead cardiovascular compound A-002 means the company will move forward with a multi-center phase 2 clinical trial (PLASMA — Phospholipase Levels And Serological Markers of Atherosclerosis). The study will examine the effect of A-002 on secretory phospholipase A2 (sPLA2) levels and other well established markers of inflammation and cardiovascular risk in patients with stable coronary artery disease due to underlying atherosclerosis.

PLASMA is expected to complete enrollment by the fourth quarter of 2007.

"PLASMA is intended to determine whether inhibition of sPLA2, an important trigger of the inflammatory response, can reduce systemic levels of inflammatory markers known to be predictors of coronary heart disease events,” stated Robert S. Rosenson, M.D., professor of Medicine and director, Lipoprotein Disorders and Clinical Atherosclerosis Research, Division of Cardiovascular Medicine at the University of Michigan and the Principal Investigator for the PLASMA trial.
“The study will serve as a basis for future trials that investigate the effects of sPLA2 inhibition on atherosclerosis progression and cardiovascular events."

For more information visit www.PLASMAtrial.com or www.anthera.com .

Related Content

Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Blood Pressure and Cholesterol-lowering Drugs Continue to Improve Survival After a Decade
News | Pharmaceuticals | August 27, 2018
Blood pressure and cholesterol-lowering drugs continue to improve survival in patients with hypertension after more...
Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

News | Pharmaceuticals | February 01, 2018
February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the Natio
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals | October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
News | Pharmaceuticals | October 04, 2017
October 4, 2017 — MyoKardia Inc.
News | Pharmaceuticals | September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
Merck Announces Results of REVEAL Outcomes Study of Anacetrapib
News | Pharmaceuticals | September 11, 2017
Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced the publication and...
Statins Associated With Improved Heart Structure and Function
News | Pharmaceuticals | May 26, 2017
Statins are associated with improved heart structure and function, according to research presented at EuroCMR 2017, May...
Feature | Pharmaceuticals | May 16, 2017
May 16, 2017 – Results of a groundbreaking clinical trial demonstrate the effectiveness of a novel, fast-acting nasal
Overlay Init